Mesenchymal Stem Cell Transplantation: Neuroprotection and Nerve Regeneration After Spinal Cord Injury
Si-Yu Chen,Rui-Lin Yang,Xiang-Chong Wu,De-Zhi Zhao,Sheng-Ping Fu,Feng-Qin Lin,Lin-Yan Li,Li-Mei Yu,Qian Zhang,Tao Zhang
DOI: https://doi.org/10.2147/jir.s428425
IF: 4.5
2023-10-20
Journal of Inflammation Research
Abstract:Si-Yu Chen, 1 Rui-Lin Yang, 1 Xiang-Chong Wu, 2 De-Zhi Zhao, 1 Sheng-Ping Fu, 2 Feng-Qin Lin, 1 Lin-Yan Li, 1 Li-Mei Yu, 1 Qian Zhang, 3 Tao Zhang 1, 2 1 Key Laboratory of Cell Engineering of Guizhou Province, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, People's Republic of China; 2 Department of Orthopaedic Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, People's Republic of China; 3 Department of Human Anatomy, Zunyi Medical University, Zunyi, Guizhou, People's Republic of China Correspondence: Tao Zhang; Qian Zhang, Email ; Spinal Cord Injury (SCI), with its morbidity characteristics of high disability rate and high mortality rate, is a disease that is highly destructive to both the physiology and psychology of the patient, and for which there is still a lack of effective treatment. Following spinal cord injury, a cascade of secondary injury reactions known as ischemia, peripheral inflammatory cell infiltration, oxidative stress, etc. create a microenvironment that is unfavorable to neural recovery and ultimately results in apoptosis and necrosis of neurons and glial cells. Mesenchymal stem cell (MSC) transplantation has emerged as a more promising therapeutic options in recent years. MSC can promote spinal cord injury repair through a variety of mechanisms, including immunomodulation, neuroprotection, and nerve regeneration, giving patients with spinal cord injury hope. In this paper, it is discussed the neuroprotection and nerve regeneration components of MSCs' therapeutic method for treating spinal cord injuries. Keywords: spinal cord injury, mesenchymal stem cell, neuroinflammation, neuroprotection, nerve regeneration Spinal cord injury (SCI) is a devastating neurological disease, which can lead to temporary or permanent impairment of motor, sensory, and autonomic nerve functions. It is estimated that the global prevalence of SCI has been increasing over the past 30 years, with 236 to 1298 patients per million people in different countries, 1,2 and each SCI patient suffers from both physical and psychological torment and also faces difficulties such as lack of financial resources and broken social relationships. 3 The pathogenesis of SCI can be divided into two stages, the first stage of injury is primary injury (such as from a fall or a traffic accident), and secondary injury ensues as a complex series of abnormal molecular signaling, inflammatory cell infiltration, inflammatory factor release, oxidative stress, vascular changes, and secondary cellular dysfunction hierarchical association reaction, which ultimately leads to apoptotic necrosis of neurons and glial cells, forming a microenvironment unfavorable to nerve regeneration and injury recovery microenvironment, aggravating the injury, 4 and when the injury enters the chronic phase of secondary damage, the already formed glial scar blocks nerve regeneration. 5,6 Patients with SCI experience sensory loss and functional defects below the injured spinal cord level as a result of primary injury and subsequent injury, which influence how severe the condition is. 1,7 No treatment has been able to properly treat SCI and improve the prognosis of SCI patients as of yet. Methylprednisolone decreases oxidative stress and inhibits lipid peroxidation in addition to treat post-SCI neuroinflammation effectively. 8,9 However, using methylprednisolone can lead to serious side effects as sepsis, pneumonia, wound infection, and gastrointestinal bleeding 10 . The glycolipid molecule gangliosides, which are found in neuronal membranes, are used as a neuroprotective agent in the treatment of SCI has several effects, including the prevention of apoptosis and anti-excitotoxic activity. However, studies have shown that after six months of ganglioside treatment, there is no difference in neurological recovery. 6,11 Mesenchymal stem cell (MSC) transplantation, is a novel therapy full of optimism and potential development, has evolved precisely because the currently available medicines to suppress neuroinflammation and neuroprotective drugs do not achieve the optimal standard of treatment for SCI. Mesenchymal stem cells (MSCs) are pluripotent stem cells that can be derived from a variety of tissues, including bone marrow, adipose, human umbilical cord blood, and others. 12,13 MSCs have the capacity for multidirectional differentiation and self-renewal, and they can differentiate into end-stage cells such as lipogenic cells, chondrogenic cells, and neuronal cells in vitro when subjected to various stimulating factors and induction media. 14–16 These qualities have caused MSCs to grad -Abstract Truncated-
immunology